Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Revelation Biosciences, Inc. (REVB : NSDQ)

• Company Description    Revelation Biosciences Inc. is a clinical-stage life sciences company. It focused on the development of immunologic-based therapies for the prevention and treatment of disease. The company's product pipeline includes REVTx-99, REVTx-200 and REVDx-501. Revelation Biosciences Inc., formerly known as Petra Acquisition Inc., is based in NEW YORK. Number of Employees: 9

• Price / Volume Information    Yesterday's Closing Price: $1.01 Daily Weekly Monthly 20 Day Moving Average: 40,507 shares Shares Outstanding: 3.98 (millions) Market Capitalization: $4.02 (millions) Beta: -0.14 52 Week High: $11.60 52 Week Low: $0.88 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.01% -7.67% 12 Week -5.61% -8.28% Year To Date -68.43% -71.70%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4660 LAJOLLA VILLAGE DRIVE SUITE 100 - SAN DIEGO,CA 92122 USA ph: 650-800-3717 fax: - mike@plrinvest.com http://www.revbiosciences.com

• General Corporate Information    Officers James Rolke - Chief Executive Officer and Chairman Chester S. Zygmont, III - Chief Financial Officer Jennifer Carver - Director Jess Roper - Director Lakhmir Chawla - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 76135L804 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/05/26 Share - Related Items Shares Outstanding: 3.98 Most Recent Split Date: 1.00 (0.25:1) Beta: -0.14 Market Capitalization: $4.02 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.88 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.18 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.39 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 96.90% vs. Previous Quarter: 67.90% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - -100.19 03/31/26 - -107.65 12/31/25 - -134.18 ROA 06/30/26 - -82.72 03/31/26 - -87.98 12/31/25 - -105.47 Current Ratio 06/30/26 - 6.22 03/31/26 - 10.02 12/31/25 - 5.41 Quick Ratio 06/30/26 - 6.22 03/31/26 - 10.03 12/31/25 - 5.41 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 2.58 03/31/26 - 3.49 12/31/25 - 1.28 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©